Scholarlink

Abstract <p><i>PRDM16</i> has been identified as a potential causal gene for cardiomyopathies, supported by reports of several cases associated with loss-of-function (LoF) variants in <i>PRDM16</i>. In this multi-centric study, we present the largest cohort to date of dilated cardiomyopathy (DCM) patients harboring <i>PRDM16</i> LoF variants, including eleven previously unreported cases. Genetic testing was conducted by three French molecular genetics laboratories (Hôpital Européen Georges Pompidou, Lyon and Nantes) on 4900 index cases with DCM and/or hypertrabeculation using targeted next-generation sequencing. The gene panel included all coding and flanking intronic regions of 59 genes, including <i>PRDM16 (NM_022114.4)</i>. In nine families, heterozygous LoF variants were detected in 11 cardiomyopathy patients. These variants included 2 deletions encompassing the entire gene, 1 multi-exonic deletion, 3 frameshift variants, 2 nonsense, and 1 splice-site variant. At diagnosis, the median age was 18.5&#xa0;years for females and 49&#xa0;years for males. Ten patients presented with DCM and 6 with hypertrabeculation. Follow-up data were available for five patients, with an average duration of 11&#xa0;years. Four patients showed an improvement in their ejection fraction. Notably, females, mainly pediatric cases, appeared to have a poorer prognosis. This study supports the hypothesis that haploinsufficiency of <i>PRDM16</i> is involved in cardiomyopathy, with females exhibiting a more severe phenotype and earlier onset. Although <i>PRDM16</i> is not currently included in the standard gene panel for cardiomyopathies, we propose that it be systematically screened in cases of DCM or symptomatic cardiac hypertrabeculation.</p> Key messages <p><UnorderedList Mark="Bullet"> <ItemContent> <p><i>PRDM16</i> haploinsufficiency leads to dilated cardiomyopathy and hypertrabeculation.</p> </ItemContent> <ItemContent> <p>More severe phenotypes and earlier disease onset are observed in females with <i>PRDM16</i> haploinsufficiency.</p> </ItemContent> <ItemContent> <p><i>PRDM16</i> should be added to the gene panels used in genetic screening for cardiomyopathy.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dilated cardiomyopathy in patients with PRDM16 haploinsufficiency

  • 期刊论文

  • 发表日期：

    2025年9月11日

查看全文
  • Clarisse Billon,
  • Gilles Millat,
  • Adeline Goudal,
  • Valerie Malan,
  • Diala Khraiche,
  • Karim Wahbi,
  • Nadine Ferrier,
  • Jean-Christophe Eicher,
  • Romain Tixier,
  • Nadir Benbrik,
  • Océane Bouchot,
  • Léa Gaudillat,
  • Annabelle Venisse,
  • Pascaline Berthome,
  • Xavier Jeunemaitre,
  • Damien Bonnet

摘要

Abstract

PRDM16 has been identified as a potential causal gene for cardiomyopathies, supported by reports of several cases associated with loss-of-function (LoF) variants in PRDM16. In this multi-centric study, we present the largest cohort to date of dilated cardiomyopathy (DCM) patients harboring PRDM16 LoF variants, including eleven previously unreported cases. Genetic testing was conducted by three French molecular genetics laboratories (Hôpital Européen Georges Pompidou, Lyon and Nantes) on 4900 index cases with DCM and/or hypertrabeculation using targeted next-generation sequencing. The gene panel included all coding and flanking intronic regions of 59 genes, including PRDM16 (NM_022114.4). In nine families, heterozygous LoF variants were detected in 11 cardiomyopathy patients. These variants included 2 deletions encompassing the entire gene, 1 multi-exonic deletion, 3 frameshift variants, 2 nonsense, and 1 splice-site variant. At diagnosis, the median age was 18.5 years for females and 49 years for males. Ten patients presented with DCM and 6 with hypertrabeculation. Follow-up data were available for five patients, with an average duration of 11 years. Four patients showed an improvement in their ejection fraction. Notably, females, mainly pediatric cases, appeared to have a poorer prognosis. This study supports the hypothesis that haploinsufficiency of PRDM16 is involved in cardiomyopathy, with females exhibiting a more severe phenotype and earlier onset. Although PRDM16 is not currently included in the standard gene panel for cardiomyopathies, we propose that it be systematically screened in cases of DCM or symptomatic cardiac hypertrabeculation.

Key messages

PRDM16 haploinsufficiency leads to dilated cardiomyopathy and hypertrabeculation.

More severe phenotypes and earlier disease onset are observed in females with PRDM16 haploinsufficiency.

PRDM16 should be added to the gene panels used in genetic screening for cardiomyopathy.